OPT101
A Non-Glucose-Based Breakthrough for Peritoneal Dialysis
Designed to address long-standing limitations in current dialysis treatment.
Designed for
- Reduced metabolic burden
- Consistent performance
- Extended treatment duration
- Personalized therapy options
An opportunity to redefine
The first innovation of its kind in over 30 years
Peritoneal dialysis has relied on the same core approaches for decades. OPT101 introduces a fundamentally new solution that is designed to improve chronic kidney disease (CKD) therapy.
Reduces metabolic stress and insulin spikes
Consistent fluid removal across all dwells
Suitable for diabetic patients — 45% of the PD population, as well as being designed to prevent CKD patients from becoming diabetic while on treatment.
Consistent performance across day and night treatments
Removes the need for glucose-based osmotic agents
A large and growing market with limited innovation
Peritoneal dialysis represents a growing global market, driven by rising chronic disease and increasing demand for home-based treatment. Despite this, innovation has remained limited.
$10B
Market
PD represents a $10B market today
$16B
by 2030
Projected to grow to $16B by 2030
+30
Years with no innovation
This is the first innovation of its kind in more than 30 years
Clinical Trials
Every new therapy goes through a series of well-defined clinical stages. OPT101 is moving through this pathway with a clear plan and strong scientific foundations.
Preclinical
Safety and performance demonstrated in accepted models.
CTA Submitted
Regulatory application filed to begin first-in-human studies in Europe.
Phase 1
Current Stage
Last patient last visit completed! Our first study in humans focuses on safety and tolerability. A small group of participants received OPT101 to confirm it behaves as expected and is well-tolerated.
Phase 2
After establishing safety, we evaluate how well OPT101 performs — identifying the optimal dose, measuring effectiveness, and providing the first clear signals of clinical benefit. A major value inflection point.
Phase 3
Large, multi-country studies confirm safety and effectiveness in a broad patient population. Positive Phase 3 results support regulatory approval and market entry.
Why Invest in Opterion
A differentiated opportunity in renal care
Kidney disease affects 850M+ people worldwide and is the 3rd fastest-growing cause of death, yet treatment has barely evolved in decades.
OPT101 removes glucose from the core of peritoneal dialysis — addressing the root cause of metabolic stress that limits current therapies.
A robust and defensible intellectual property position protects the innovation and its commercial potential.
Built on well-understood mechanisms and validated in accepted preclinical models, de-risking the path to the clinic.
A scalable, home-based model that improves outcomes while lowering the cost burden on healthcare systems.
Clear strategic interest from dialysis incumbents and pharma, offering several routes to liquidity.
An experienced team with a history of building and delivering breakthrough medical innovations.